G

GemPharmatech Co Ltd
SSE:688046

Watchlist Manager
GemPharmatech Co Ltd
SSE:688046
Watchlist
Price: 12.94 CNY -6.71% Market Closed
Market Cap: 5.3B CNY
Have any thoughts about
GemPharmatech Co Ltd?
Write Note

GemPharmatech Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GemPharmatech Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
G
GemPharmatech Co Ltd
SSE:688046
Pre-Tax Income
ÂĄ161.3m
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Pre-Tax Income
ÂĄ10.5B
CAGR 3-Years
31%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Pre-Tax Income
ÂĄ2.2B
CAGR 3-Years
14%
CAGR 5-Years
37%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Pre-Tax Income
ÂĄ3.7B
CAGR 3-Years
3%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Pre-Tax Income
ÂĄ1.3B
CAGR 3-Years
-25%
CAGR 5-Years
8%
CAGR 10-Years
24%
W
WuXi XDC Cayman Inc
HKEX:2268
Pre-Tax Income
ÂĄ359.6m
CAGR 3-Years
123%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GemPharmatech Co Ltd
Glance View

Market Cap
5.3B CNY
Industry
Life Sciences Tools & Services

GemPharmatech Co., Ltd. engages in research and development, manufacture, and sale of experimental mouse models. The company is headquartered in Nanjing, Jiangsu and currently employs 1,342 full-time employees. The company went IPO on 2022-04-25. The firm uses gene-editing and other technologies to produce mouse models. The firm also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.

Intrinsic Value
20.3 CNY
Undervaluation 36%
Intrinsic Value
Price
G

See Also

What is GemPharmatech Co Ltd's Pre-Tax Income?
Pre-Tax Income
161.3m CNY

Based on the financial report for Dec 31, 2023, GemPharmatech Co Ltd's Pre-Tax Income amounts to 161.3m CNY.

What is GemPharmatech Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
21%

Over the last year, the Pre-Tax Income growth was -7%. The average annual Pre-Tax Income growth rates for GemPharmatech Co Ltd have been 21% over the past three years .

Back to Top